Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.75 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518377 | 1.00 | CYSLTR2 (0.75) | CYSLTR2NR1H4PLA2G4BSSTR3MMP2 | |
| SCHEMBL4523085 | 0.92 | CYSLTR2 (0.64) | CYSLTR2NR1H4FFAR1 | |
| SCHEMBL4523082 | 0.92 | CYSLTR2 (0.64) | CYSLTR2NR1H4FFAR1 | |
| SCHEMBL4509647 | 0.87 | CYSLTR2 (0.67) | CYSLTR2NR1H4PLA2G4BPOLBCASP6 | |
| SCHEMBL4525419 | 0.86 | CYSLTR2 (0.57) | CYSLTR2 | |
| SCHEMBL4525421 | 0.86 | CYSLTR2 (0.57) | CYSLTR2 | |
| SCHEMBL4512506 | 0.86 | CYSLTR2 (1.00) | CYSLTR2NR1H4PLA2G4BPOLBCASP6 | |
| SCHEMBL29438768 | 0.86 | CYSLTR2 (1.00) | CYSLTR2NR1H4PLA2G4BPOLBCASP6 | |
| SCHEMBL13918385 | 0.85 | CYSLTR2 (0.90) | CYSLTR2NR1H4PLA2G4BPOLBCASP6 | |
| SCHEMBL13918344 | 0.85 | CYSLTR2 (0.90) | CYSLTR2NR1H4PLA2G4BPOLBCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | CYSLTR2 1426/4885NR1H4 177/4885PLA2G4B 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.